Login
Super Investors ALPS Medical Breakthroughs ETF

ALPS Medical Breakthroughs ETF

Alps ETF Trust · net assets $240M · 110 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 100.0% · STIV: 0.0% · DE: 0.0%

Financial position

Total assets
$240M
Total liabilities
$95.7K
Net assets
$240M
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0
Cash not reported in Parts C or D
$0

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $4.46M $15M $29.1M
Reinvestment $0 $0 $0
Redemptions $5.23M $0 $0
Net realized gain (non-derivative) $8.79M -$2.75K -$2.83K
Net unrealized appreciation (non-derivative) $20.7M -$3.76M $9.33M

The three months of the reporting period, as filed; month 3 ends August 31, 2026.

Filing details

Registrant
Alps ETF Trust
Registrant CIK
1414040
Registrant LEI
549300VF1907NYC4WM31
Series
ALPS Medical Breakthroughs ETF
Series ID
S000047823
Series LEI
549300UUE13R3N0UVB96
SEC file number
811-22175
Address
1290 BROADWAY SUITE 1000, DENVER, US-CO, 80203, US
Phone
3036232577
Form
NPORT-P
Filed
October 29, 2026
Report period ends
November 30, 2026
Report month ends
August 31, 2026
Accession number
000104916926002772
Holding Value % of net assets
Crinetics Pharmaceuticals Inc EC $11M 4.60%
Apogee Therapeutics Inc EC $10.3M 4.29%
Cg Oncology Inc EC $8.17M 3.41%
Travere Therapeutics Inc EC $7.59M 3.16%
Xenon Pharmaceuticals Inc EC $7.17M 2.99%
Dianthus Therapeutics Inc EC $7.11M 2.96%
Oruka Therapeutics Inc EC $6.88M 2.87%
Acadia Pharmaceuticals Inc EC $6.1M 2.54%
Edgewise Therapeutics Inc EC $5.54M 2.31%
Definium Therapeutics Inc EC $5.34M 2.23%
Dyne Therapeutics Inc EC $5.18M 2.16%
Veradermics Inc EC $5.06M 2.11%
Relay Therapeutics Inc EC $4.93M 2.05%
Denali Therapeutics Inc EC $4.65M 1.94%
Amylyx Pharmaceuticals Inc EC $4.63M 1.93%
Ideaya Biosciences Inc EC $4.34M 1.81%
Structure Therapeutics Inc EC $4.02M 1.68%
Tarsus Pharmaceuticals Inc EC $3.93M 1.64%
Celldex Therapeutics Inc EC $3.83M 1.60%
Immunome Inc EC $3.83M 1.60%
Disc Medicine Inc EC $3.7M 1.54%
Newamsterdam Pharma Co Nv EC $3.65M 1.52%
Mbx Biosciences Inc EC $3.61M 1.50%
Zai Lab Ltd EC $3.42M 1.42%
Viridian Therapeutics Inc EC $3.15M 1.31%
Sellas Life Sciences Group Inc EC $3.06M 1.28%
Biocryst Pharmaceuticals Inc EC $3.04M 1.27%
Vera Therapeutics Inc EC $3.02M 1.26%
Nektar Therapeutics EC $2.98M 1.24%
Rapport Therapeutics Inc EC $2.87M 1.19%
Nuvation Bio Inc EC $2.86M 1.19%
Mineralys Therapeutics Inc EC $2.79M 1.16%
Sarepta Therapeutics Inc EC $2.74M 1.14%
Palvella Therapeutics Inc EC $2.68M 1.12%
Zenas Biopharma Inc EC $2.51M 1.05%
Vericel Corp EC $2.51M 1.05%
Xencor Inc EC $2.49M 1.04%
Agios Pharmaceuticals Inc EC $2.47M 1.03%
Kailera Therapeutics Inc EC $2.46M 1.03%
Generate Biomedicines Inc EC $2.41M 1.00%
Stoke Therapeutics Inc EC $2.4M 1.00%
Lakefront Biotherapeutics Nv EC $2.28M 0.95%
Immunocore Holdings PLC EC $2.28M 0.95%
Compass Pathways PLC EC $2.25M 0.94%
Taysha Gene Therapies Inc EC $2.02M 0.84%
Bicara Therapeutics Inc EC $1.87M 0.78%
Tyra Biosciences Inc EC $1.84M 0.77%
Maze Therapeutics Inc EC $1.81M 0.76%
Arrivent Biopharma Inc EC $1.73M 0.72%
Lb Pharmaceuticals Inc EC $1.68M 0.70%
Immatics Nv EC $1.58M 0.66%
Meiragtx Holdings PLC EC $1.57M 0.65%
Seaport Therapeutics Inc EC $1.57M 0.65%
Alto Neuroscience Inc EC $1.54M 0.64%
Mannkind Corp EC $1.53M 0.64%
Vor Biopharma Inc EC $1.49M 0.62%
Corvus Pharmaceuticals Inc EC $1.46M 0.61%
Kura Oncology Inc EC $1.39M 0.58%
Candel Therapeutics Inc EC $1.19M 0.49%
Geron Corp EC $1.18M 0.49%

Showing top 60 of 110 holdings.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support